Please use this identifier to cite or link to this item:
|Title:||ROS1 as a 'druggable' receptor tyrosine kinase: Lessons learned from inhibiting the ALK pathway|
non-small-cell lung cancer
ROS1 receptor tyrosine kinase
|Citation:||Ou, S.-H.I., Tan, J., Yen, Y., Soo, R.A. (2012-04). ROS1 as a 'druggable' receptor tyrosine kinase: Lessons learned from inhibiting the ALK pathway. Expert Review of Anticancer Therapy 12 (4) : 447-456. ScholarBank@NUS Repository. https://doi.org/10.1586/era.12.17|
|Abstract:||ROS1 is one of 58 receptor tyrosine kinases, and one of two orphan receptor tyrosine kinases where its ligand is unknown. ROS1 is evolutionarily related to ALK. ROS1 rearrangement was discovered in glioblastoma in 1987, in non-small-cell lung cancer (NSCLC) in 2007, and in cholangiocarcinoma in 2011. While the clinicopathologic characteristics of ROS1-rearranged glioblastoma and cholangiocarcinoma patients remain to be defined, the clinicopathologic characteristics of ROS1-rearranged NSCLC patients have recently been described. Although ROS1 shares only 49% amino acid sequence homology with ALK in the kinase domains, several ALK inhibitors have demonstrated in vitro inhibitory activity against ROS1. With the recent US approval of crizotinib, a multi-targeted ALK/MET kinase inhibitor, for the treatment of ALK-rearranged NSCLC, attention has turned to ROS1-rearranged tumors, especially NSCLC. The next few years should witness a rapid pace of clinical research in ROS1-rearranged tumors utilizing available ALK inhibitors. © 2012 Expert Reviews Ltd.|
|Source Title:||Expert Review of Anticancer Therapy|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on May 20, 2018
WEB OF SCIENCETM
checked on Apr 23, 2018
checked on May 11, 2018
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.